In this roundtable discussion, led by Prof. Christian Gratzke (DE), experts discuss PARP inhibitors as a treatment prostate cancer and bladder cancer. Prof. Bertrand Tombal (BE) presented “PARP inhibitors: For which mutations and when?”, followed by a lecture from Dr. Elena Castro (ES) on “What is in the pipeline for PARPi?”, and Prof. Andrea Necchi (IT) with a presentation on “What’s next after immune checkpoint inhibitors?”.
